Michael Cole

4.4k total citations · 1 hit paper
94 papers, 3.2k citations indexed

About

Michael Cole is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Neurology. According to data from OpenAlex, Michael Cole has authored 94 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 22 papers in Pediatrics, Perinatology and Child Health and 21 papers in Neurology. Recurrent topics in Michael Cole's work include Neuroblastoma Research and Treatments (19 papers), Cancer therapeutics and mechanisms (13 papers) and Childhood Cancer Survivors' Quality of Life (11 papers). Michael Cole is often cited by papers focused on Neuroblastoma Research and Treatments (19 papers), Cancer therapeutics and mechanisms (13 papers) and Childhood Cancer Survivors' Quality of Life (11 papers). Michael Cole collaborates with scholars based in United Kingdom, United States and Australia. Michael Cole's co-authors include Andrew D.J. Pearson, Alan V. Boddy, Gareth J. Veal, L Price, Alan Craft, Étienne Chatelut, Deborah A. Tweddle, Brian J. Anderson, Barry Wilkins and Malcolm Coulthard and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Biochemical Journal.

In The Last Decade

Michael Cole

91 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

2013 412 citations Michael Cole et al. profile →

Peers

Countries citing papers authored by Michael Cole

Since Specialization

Citations

This map shows the geographic impact of Michael Cole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Cole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Cole more than expected).

Fields of papers citing papers by Michael Cole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Cole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Cole. The network helps show where Michael Cole may publish in the future.

Co-authorship network of co-authors of Michael Cole

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Cole. A scholar is included among the top collaborators of Michael Cole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Cole. Michael Cole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Caesarean myomectomy in pregnant women with uterine fibroids 2025 ·Cochrane Database of Systematic Reviews ·(unknown), Michael Cole, Diane E. Brown, Ruaraidh Hill, Marty Chaplin, (unknown), Ffion Curtis	0
2	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial 2021 ·The Lancet Rheumatology ·Arthur G. Pratt, Stefan Siebert, Michael Cole, Deborah Stocken, Christina Yap, Stephen Kelly, (unknown), Amy Cranston, (unknown), (unknown), Sheelagh Frame, Wan‐Fai Ng, Christopher D. Buckley, Iain B. McInnes, Andrew Filer, John D. Isaacs	38
3	Adjuvant rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial 2019 ·BMJ Open ·Michael Cole, Ann Marie Hynes, Denise Howel, (unknown), Mario Abinun, Amit Allahabadia, Timothy Barrett, Kristien Boelaert, Amanda J. Drake, Paul Dimitri, Jeremy Kirk, Nicola N. Zammitt, Simon H. S. Pearce, Tim Cheetham	5
4	Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer 2014 ·Clinical Pharmacokinetics ·Christopher Hill, Michael Cole, Julie Errington, (unknown), Alan V. Boddy, Gareth J. Veal	36
5	Adaptive Dosing Approaches to the Individualization of 13- Cis -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma 2012 ·Clinical Cancer Research ·Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth, (unknown), Michael Cole, Ann K. Daly, Andrew D.J. Pearson, Alan V. Boddy	38
6	Rapid Diagnosis of Medulloblastoma Molecular Subgroups 2011 ·Clinical Cancer Research ·Ed C. Schwalbe, Janet C. Lindsey, (unknown), Twala L. Hogg, Michael Cole, Hisham Megahed, Sarra Ryan, Meryl E. Lusher, Michael D. Taylor, Richard J. Gilbertson, David W. Ellison, Simon Bailey, Steven C. Clifford	58
7	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma 2011 ·Acta Neuropathologica ·Sarra Ryan, Ed C. Schwalbe, Michael Cole, Yuan Lu, Meryl E. Lusher, Hisham Megahed, K O’Toole, Sarah Leigh Nicholson, László Bognár, Miklós Garami, Péter Hauser, Andrey Korshunov, Stefan M. Pfister, Daniel Williamson, Roger Taylor, David W. Ellison, Simon Bailey, Steven C. Clifford	65
8	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials 2010 ·Cancer Chemotherapy and Pharmacology ·Tomasz Zaremba, Huw D. Thomas, Michael Cole, Elizabeth Ruth Plummer, Nicola J. Curtin	17
9	Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors 2009 ·European Journal of Cancer ·Roderick Skinner, (unknown), L Price, Michael Cole, Alan Craft, Andrew D.J. Pearson	91
10	Estimation of renal function and its potential impact on carboplatin dosing in children with cancer 2008 ·British Journal of Cancer ·(unknown), Girish Chinnaswamy, Michael Cole, Alan V. Boddy, M.J. Keir, L Price, (unknown), Martin English, Gareth J. Veal	9
11	Population Pharmacokinetic Investigation of Actinomycin‐D in Children and Young Adults 2007 ·The Journal of Clinical Pharmacology ·(unknown), Leonid Gibiansky, (unknown), (unknown), Michael Cole, Gareth J. Veal, Alan V. Boddy, (unknown), Jeffrey S. Barrett	21
12	p53 is Nuclear and Functional in Both Undifferentiated and Differentiated Neuroblastoma 2007 ·Cell Cycle ·Lindi Chen, Archie J. Malcolm, Katrina Wood, Michael Cole, S. Variend, C. Cullinane, Andrew D.J. Pearson, John Lunec, Deborah A. Tweddle	36
13	Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non-Desmoplastic Medulloblastomas 2003 ·Journal of Neuropathology & Experimental Neurology ·(unknown), (unknown), Roger Taylor, Michael Cole, Andrew D.J. Pearson, Steven C. Clifford, David W. Ellison	77
14	The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system 2002 ·British Journal of Cancer ·(unknown), (unknown), Michael Cole, Robert Perry, Andrew Pearson, John Lunec	11
15	biparous:A Novel bHLH Gene Expressed in Neuronal and Glial Precursors inDrosophila, 1999 ·Developmental Biology ·Andrew B. G. Bush, Yasushi Hiromi, Michael Cole	1
16	Avirulence of Candida albicans auxotrophic mutants in a rat model of oropharyngeal candidiasis 1995 ·FEMS Microbiology Letters ·Michael Cole	0
17	The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion 1995 ·Cancer Chemotherapy and Pharmacology ·Alan V. Boddy, Michael Cole, Andrew D.J. Pearson, Jeffrey R. Idle	51
18	Screening Infants For Neuroblastoma: The Parents' Perspective 1994 ·Pediatric Hematology and Oncology ·Sue Bell, Louise Parker, Michael Cole, Alan Craft	6
19	False positive results in a neuroblastoma screening programme 1994 ·Medical and Pediatric Oncology ·Susan Bell, Louise Parker, Alan Craft, Gordon Dale, Andrew C. McGill, John Seviour, Michael Cole, Julian Smith	11
20	A Trial of the Prostaglandin E1 Analogue, Enisoprost, to Reverse Chronic Cyclosporine-Associated Renal Dysfunction 1992 ·American Journal of Kidney Diseases ·Raymond Pollak, Richard J. Knight, Martin F. Mozes, Michael S. Maddux, (unknown), Charles Van Buren, Richard M. Lewis, Emma Scott, Michael Cole, (unknown), M Morán, B D Kahan	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact